Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
about
Evolution of animal models in cancer vaccine developmentTrafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsDendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceStrategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapyCD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccineImmunity and immune suppression in human ovarian cancer.Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumorsThe ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.Immunogenic HER-2/neu peptides as tumor vaccines.Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patientsRecruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseAntibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.Re-purposing cancer therapeutics for breast cancer immunotherapyHepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection.Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.Cancer immunotherapy using Listeria monocytogenes and listerial virulence factorsThe immune system in the pathogenesis of ovarian cancer.Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized miceHepatitis B virus surface antigen as delivery vector can enhance Chlamydia trachomatis MOMP multi-epitope immune response in mice.Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma.Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue.HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer.
P2860
Q28080739-C91B5799-7709-4EEB-BD33-0F6D91700D4DQ28732041-306E2A5C-3F7C-448E-92D0-9272F4229FC2Q30318566-F7274BA0-7462-4ADB-9417-DEA1651BB97AQ33823499-C6825B84-1C37-4C62-A405-6A5767DB3CD0Q34364276-A2F1A485-BFC2-4925-BBAE-03978B6FEF22Q34477650-80955228-C23C-4EBC-8D14-4D74433A8526Q34556927-66276BD4-22B5-4CB9-995C-F1A4E6C298FCQ34725101-FDE23486-46A1-4D5E-A8CD-F707223EFA80Q35130450-860A1CB6-5E5B-4530-9F8D-0B8F26DE7DC4Q35138135-4B4FC4B7-F47A-4999-B60A-5B2A4E143293Q35182373-44515ACD-BA95-4BA0-AF93-B8CAF2DF6908Q35329234-1F966023-B8EE-4F9A-AEA5-A554E14928C2Q35417571-AF4A1205-CEC7-46B5-9017-566B24E853E3Q35543083-11F7AC76-FD62-42AE-9E44-4F804FC12A12Q35949083-AACE99BB-5BF9-4027-9EA9-539FE3A95194Q36032635-BC73F8C1-8D05-4E19-9110-E36F518A1FB5Q36158153-A402DF4B-0C88-49DE-B1F4-472B0EF05782Q36198661-646A9BAA-DCC6-46AF-8887-984294A73917Q36399737-206F7090-B6A7-4837-85A8-D74E22BD6B0FQ36402967-17EDCA69-66FA-4383-B143-41D88077A5B9Q36532521-1FFD8276-A15B-45D0-8084-8190538D3926Q36638402-B17F6087-D4F2-41FF-97D4-19FE7739B4ABQ36685400-81576F6F-D70B-4511-B204-621A42A20290Q37216446-4929C282-9EFC-4D3D-8C35-C8B1472A72F6Q37391236-9C81186A-DABF-4570-BA95-CA39A623163EQ37613407-2EDFC5C1-B271-4694-960C-37BC7639CFC1Q37725761-0E6E6734-AA09-46EF-AC61-2BB23CCB2D2DQ37845082-F78637FC-7A74-4A8F-9EDB-AC37C502501EQ38093572-48D08B89-A034-4B96-8870-E073CF1DFE4AQ38715342-43518BDF-EA23-43E3-92E5-EFD5D31A6EE4Q39885468-52DFBEA8-9861-462F-B93E-2A2242EF1A62Q40499571-2E0171A5-5682-492B-B9E1-F4FD5C62EBB4Q40584258-7044B8F3-372B-42DF-82B0-E67195A31D61Q44788642-B45A9C04-3563-465D-9B7D-29CB60F80E52Q45858638-25313267-5544-49EE-AF0F-ACBA281B6310Q53482870-94C9E3E2-233B-4581-BC44-2455E93889D6Q54977101-5322FE33-439B-40DE-9FA4-D30C5544FCB9
P2860
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Identification and characteriz ...... rom HER-2/neu-transgenic mice.
@en
type
label
Identification and characteriz ...... rom HER-2/neu-transgenic mice.
@en
prefLabel
Identification and characteriz ...... rom HER-2/neu-transgenic mice.
@en
P2093
P1476
Identification and characteriz ...... rom HER-2/neu-transgenic mice.
@en
P2093
Anne M Ercolini
Jean-Pascal H Machiels
Jill E Slansky
Martin Giedlen
R Todd Reilly
Yi Cheng Chen
P304
P356
10.4049/JIMMUNOL.170.8.4273
P407
P577
2003-04-01T00:00:00Z